"Receptors, Fc" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecules found on the surface of some, but not all, B-lymphocytes, T-lymphocytes, and macrophages, which recognize and combine with the Fc (crystallizable) portion of immunoglobulin molecules.
| Descriptor ID |
D011961
|
| MeSH Number(s) |
D12.776.543.750.705.871
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Fc".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Fc".
This graph shows the total number of publications written about "Receptors, Fc" by people in this website by year, and whether "Receptors, Fc" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 2 | 2 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Fc" by people in Profiles.
-
Borghi S, Bournazos S, Thulin NK, Li C, Gajewski A, Sherwood RW, Zhang S, Harris E, Jagannathan P, Wang LX, Ravetch JV, Wang TT. FcRn, but not Fc?Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci U S A. 2020 06 09; 117(23):12943-12951.
-
Knorr DA, Ravetch JV. Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism. Clin Cancer Res. 2019 02 01; 25(3):904-906.
-
Bournazos S, Ravetch JV. Diversification of IgG effector functions. Int Immunol. 2017 07 01; 29(7):303-310.
-
Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV. Signaling by Antibodies: Recent Progress. Annu Rev Immunol. 2017 04 26; 35:285-311.
-
Li T, DiLillo DJ, Bournazos S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A. 2017 03 28; 114(13):3485-3490.
-
Dahan R, Ravetch JV. Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement. Cancer Cell. 2016 09 12; 30(3):369-371.
-
DiLillo DJ, Palese P, Wilson PC, Ravetch JV. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016 Feb; 126(2):605-10.
-
Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV. Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell. 2015 Jul 02; 162(1):160-9.
-
Fiebiger BM, Maamary J, Pincetic A, Ravetch JV. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc Natl Acad Sci U S A. 2015 May 05; 112(18):E2385-94.
-
Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, Ravetch JV, Nussenzweig MC. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell. 2014 Aug 28; 158(5):989-999.